On September 27, 2023 Beyond Cancer, Ltd. (the "Company"), an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, reported that the Company will present data at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting 2023, which is scheduled to be held November 3rd – 5th at the San Diego Convention Center in San Diego, California (Press release, Beyond Air, SEP 27, 2023, View Source [SID1234635463]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the Company’s poster presentation are as follows:
Title: Phase 1 study of ultra-high concentration nitric oxide ablation in relapsed refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies
Location: San Diego Convention Center, Exhibit Hall A and B1,
Abstract Number: 733
Date: Friday, November 3, 2023, 9 a.m. – 7 p.m. PDT
Authors:
Amichay Meirovitz, MD, Soroka University Medical Center, Beersheba, Israel,
David Greenberg, MD, Soroka University Medical Center, Beersheba, Israel,
Amir Avniel, Beyond Air, Rehovot, Israel,
Jedidiah Monson, MD, Beyond Cancer, Atlanta, GA, USA
About Nitric Oxide
Nitric Oxide (NO) is a potent molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens.